Top

Clinical and Translational Oncology

Published in:

01-04-2017 | Research Article

Serum Cyr61 as a potential biomarker for diagnosis of colorectal cancer

Authors: Y. F. Song, Z. B. Xu, X. J. Zhu, X. Tao, J. L. Liu, F. L. Gao, C. L. Wu, B. Song, Q. Lin

Published in: Clinical and Translational Oncology | Issue 4/2017

Abstract

Purpose

To determine the sensitivity and specificity of serum Cyr61 as a potential biomarker for the diagnosis of colorectal cancer (CRC) and to assess the association between serum Cyr61 level and CRC clinicopathological status.

Methods

We used an enzyme-linked immunosorbent assay to measure serum Cyr61 in patients with CRC, patients with colorectal adenomas, and healthy controls. We also analyzed the relationship between serum Cyr61 and clinicopathological features of CRC patients. The levels of serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) were quantified using the Roche Cobas 6000 Analyzer. The sensitivity and specificity of Cyr61, CEA, CA19-9 and CEA + CA19-9 were evaluated by receiver operating characteristic (ROC) analysis.

Results

The serum level of Cyr61 was significantly increased in CRC patients compared with colorectal adenoma patients and healthy controls (p < 0.001). Furthermore, the area under the ROC curve for Cyr61 was 0.935 (95 % confidence interval 0.902–0.968), higher than that for CEA + CA19-9 (0.827, 95 % confidence interval: 0.783–0.871). Use of a Cyr61 cutoff value of 92.0 pg/mL allowed distinguishing CRC patients and healthy controls with a sensitivity of 83 % and a specificity of 97 %. Among CRC patients, an elevated level of serum Cyr61 was significantly associated with more advanced TNM stage (p < 0.0042), lymph node metastasis (p < 0.0088), and vascular invasion (p = 0.0027).

Conclusion

Cyr61 has potential as a serum biomarker for the diagnosis of CRC and for assessment of the clinicopathological status of CRC.

Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):104–17. doi:10.3322/caac.21220.CrossRefPubMed

Liu S, Zheng R, Zhang M, Zhang S, Sun X, Chen W. Incidence and mortality of colorectal cancer in China, 2011. Chin J Cancer Res. 2015;27(1):22–8. doi:10.3978/j.issn.1000-9604.2015.02.01.CrossRefPubMedPubMedCentral

Yoruker EE, Holdenrieder S, Gezer U. Blood-based biomarkers for diagnosis, prognosis and treatment of colorectal cancer. Clin Chim Acta. 2016;455:26–32. doi:10.1016/j.cca.2016.01.016.CrossRefPubMed

Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC. Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014;15(4):389–97. doi:10.4161/cbt.27625.CrossRefPubMedPubMedCentral

Newton KF, Newman W, Hill J. Review of biomarkers in colorectal cancer. Colorectal Dis. 2012;14(1):3–17. doi:10.1111/j.1463-1318.2010.02439.x.CrossRefPubMed

Chen Y, Du XY. Functional properties and intracellular signaling of CCN1/Cyr61. J Cell Biochem. 2007;100(6):1337–45. doi:10.1002/jcb.21194.CrossRefPubMed

Xie D, Miller CW, O’Kelly J, Nakachi K, Sakashita A, Said JW, et al. Breast cancer. Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease. J Biol Chem. 2001;276(17):14187–94. doi:10.1074/jbc.M009755200.PubMed

O’Kelly J, Chung A, Lemp N, Chumakova K, Yin D, Wang HJ, et al. Functional domains of CCN1 (Cyr61) regulate breast cancer progression. Int J Oncol. 2008;33(1):59–67.PubMed

D’Antonio KB, Toubaji A, Albadine R, Mondul AM, Platz EA, Netto GJ, et al. Extracellular matrix associated protein CYR61 is linked to prostate cancer development. J Urol. 2010;183(4):1604–10. doi:10.1016/j.juro.2009.12.006.CrossRefPubMedPubMedCentral

10.

Terada N, Kulkarni P, Getzenberg RH. Cyr61 is a potential prognostic marker for prostate cancer. Asian J Androl. 2012;14(3):405–8. doi:10.1038/aja.2011.149.CrossRefPubMedPubMedCentral

11.

Zhao ZS, Li L, Wang HJ, Wang YY. Expression and prognostic significance of CEACAM6, ITGB1, and CYR61 in peripheral blood of patients with gastric cancer. J Surg Oncol. 2011;104(5):525–9. doi:10.1002/jso.21984.CrossRefPubMed

12.

Kok SH, Chang HH, Tsai JY, Hung HC, Lin CY, Chiang CP, et al. Expression of Cyr61 (CCN1) in human oral squamous cell carcinoma: an independent marker for poor prognosis. Head Neck. 2010;32(12):1665–73. doi:10.1002/hed.21381.CrossRefPubMed

13.

Feng P, Wang B, Ren EC. Cyr61/CCN1 is a tumor suppressor in human hepatocellular carcinoma and involved in DNA damage response. Int J Biochem Cell Biol. 2008;40(1):98–109. doi:10.1016/j.biocel.2007.06.020.CrossRefPubMed

14.

Jeong D, Heo S, Sung Ahn T, Lee S, Park S, Kim H, et al. Cyr61 expression is associated with prognosis in patients with colorectal cancer. BMC Cancer. 2014;14:164. doi:10.1186/1471-2407-14-164.CrossRefPubMedPubMedCentral

15.

Ladwa R, Pringle H, Kumar R, West K. Expression of CTGF and Cyr61 in colorectal cancer. J Clin Pathol. 2011;64(1):58–64. doi:10.1136/jcp.2010.082768.CrossRefPubMed

16.

Chen VW, Hsieh MC, Charlton ME, Ruiz BA, Karlitz J, Altekruse SF, et al. Analysis of stage and clinical/prognostic factors for colon and rectal cancer from SEER registries: AJCC and collaborative stage data collection system. Cancer. 2014;120(Suppl 23):3793–806. doi:10.1002/cncr.29056.CrossRefPubMedPubMedCentral

17.

Tsai MS, Bogart DF, Li P, Mehmi I, Lupu R. Expression and regulation of Cyr61 in human breast cancer cell lines. Oncogene. 2002;21(6):964–73. doi:10.1038/sj.onc.1205131.CrossRefPubMed

18.

Bleau AM, Planque N, Perbal B. CCN proteins and cancer: two to tango. Front Biosci. 2005;10:998–1009.CrossRefPubMed

19.

Li J, Ye L, Owen S, Weeks HP, Zhang Z, Jiang WG. Emerging role of CCN family proteins in tumorigenesis and cancer metastasis (review). Int J Mol Med. 2015;36(6):1451–63. doi:10.3892/ijmm.2015.2390.PubMedPubMedCentral

20.

Shah R, Jones E, Vidart V, Kuppen PJ, Conti JA, Francis NK. Biomarkers for early detection of colorectal cancer and polyps: systematic review. Cancer Epidemiol Biomark Prev. 2014;23(9):1712–28. doi:10.1158/1055-9965.EPI-14-0412.CrossRef

21.

Booth RA. Minimally invasive biomarkers for detection and staging of colorectal cancer. Cancer Lett. 2007;249(1):87–96. doi:10.1016/j.canlet.2006.12.021.CrossRefPubMed

22.

Obrocea FL, Sajin M, Marinescu EC, Stoica D. Colorectal cancer and the 7th revision of the TNM staging system: review of changes and suggestions for uniform pathologic reporting. Rom J Morphol Embryol. 2011;52(2):537–44.PubMed

23.

Jiang WG, Watkins G, Fodstad O, Douglas-Jones A, Mokbel K, Mansel RE. Differential expression of the CCN family members Cyr61, CTGF and Nov in human breast cancer. Endocr Relat Cancer. 2004;11(4):781–91. doi:10.1677/erc.1.00825.CrossRefPubMed

24.

Schmitz P, Gerber U, Jungel E, Schutze N, Blaheta R, Bendas G. Cyr61/CCN1 affects the integrin-mediated migration of prostate cancer cells (PC-3) in vitro. Int J Clin Pharmacol Ther. 2013;51(1):47–50.CrossRefPubMed

25.

Lin J, Huo R, Wang L, Zhou Z, Sun Y, Shen B, et al. A novel anti-Cyr61 antibody inhibits breast cancer growth and metastasis in vivo. Cancer Immunol Immunother. 2012;61(5):677–87. doi:10.1007/s00262-011-1135-y.CrossRefPubMed

26.

Lin MT, Zuon CY, Chang CC, Chen ST, Chen CP, Lin BR, et al. Cyr61 induces gastric cancer cell motility/invasion via activation of the integrin/nuclear factor-kappaB/cyclooxygenase-2 signaling pathway. Clin Cancer Res. 2005;11(16):5809–20. doi:10.1158/1078-0432.CCR-04-2639.CrossRefPubMed

27.

Fujii T, Sutoh T, Morita H, Yajima R, Yamaguchi S, Tsutsumi S, et al. Vascular invasion, but not lymphatic invasion, of the primary tumor is a strong prognostic factor in patients with colorectal cancer. Anticancer Res. 2014;34(6):3147–51.PubMed

28.

Naito Y, Goto K, Nagai K, Ishii G, Nishimura M, Yoshida J, et al. Vascular invasion is a strong prognostic factor after complete resection of node-negative non-small cell lung cancer. Chest. 2010;138(6):1411–7. doi:10.1378/chest.10-0185.CrossRefPubMed

29.

Betge J, Langner C. Vascular invasion, perineural invasion, and tumour budding: predictors of outcome in colorectal cancer. Acta Gastroenterol Belg. 2011;74(4):516–29.PubMed

Title: Serum Cyr61 as a potential biomarker for diagnosis of colorectal cancer
Authors: Y. F. Song
Z. B. Xu
X. J. Zhu
X. Tao
J. L. Liu
F. L. Gao
C. L. Wu
B. Song
Q. Lin
Publication date: 01-04-2017
Publisher: Springer International Publishing
Published in: Clinical and Translational Oncology / Issue 4/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-016-1560-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2017

Predictive value of hypoxia in advanced head and neck cancer after treatment with hyperfractionated radio-chemotherapy and hypoxia modification

Comparison of clinicopathological features and prognosis of gastric cancer located in the lesser and greater curve

Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain

Hypofractionated boost after whole breast irradiation in breast carcinoma: chronic toxicity results and cosmesis

Telomeres and telomerase in the clinical management of colorectal cancer

Accelerated hypofractionated radiation therapy (AHRT) for non-small-cell lung cancer: can we leave standard fractionation?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer